gemtuzumab ozogamicin in frontline aml therapy
Published 4 years ago • 311 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
1:55
treatment of intermediate-risk aml with gemtuzumab ozogamicin
-
2:07
adcs for aml: gemtuzumab ozogamicin
-
3:04
immunotherapy for frontline treatment of all: inotuzumab ozogamicin and blinatumomab
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
1:23
azacitidine and venetoclax /- gemtuzumab ozogamicin in pediatric patients with r/r acute leukemias
-
13:14
hematology chapter 30 cytogenetics
-
4:34
the genetics of acute myeloid leukemia (aml)
-
32:19
acute myeloid leukemia 07 m3 practical
-
6:21
gemtuzumab ozogamicin for aml: challenges and reapproval
-
1:36
targeted therapy for aml
-
1:21
gemtuzumab-based induction chemotherapy with midostaurin in flt3-mutated aml
-
2:32
isal session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in aml and apl
-
4:18
use of gemtuzumab ozogamicin in cbf-aml
-
4:09
adcs for aml: potential alternatives to gemtuzumab ozogamicin
-
1:54
phase i/ib trial of talazoparib plus gemtuzumab ozogamicin in r/r aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:41
aml18 trial: fractionated vs single dose of gemtuzumab ozogamicin in older patients with aml
-
2:58
standard vs high-dose anthracycline vs anthracycline gemtuzumab ozogamicin in favorable risk aml
-
2:04
the impact of cytogenetics on treatment decisions in aml
-
1:38
lba: komet-001 - ziftomenib monotherapy in r/r npm1-mutated aml
-
1:59
chip-aml22 master and linked trial: gemtuzumab ozogamicin and quizartinib in newly diagnosed aml
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds